A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy
Autor: | João Pedreira Duprat Neto, Eduardo Bertolli, Mariana Petaccia de Macedo, Clovis Antonio Lopes Pinto, Vinicius Fernando Calsavara |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male medicine.medical_specialty Skin Neoplasms Adolescent Sentinel lymph node Dermatology Single Center Risk Assessment Breslow Thickness Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Risk Factors Skin Ulcer Biopsy Humans Medicine Child Melanoma Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test Sentinel Lymph Node Biopsy business.industry Retrospective cohort study Middle Aged Nomogram medicine.disease Tumor Burden Nomograms Child Preschool Lymphatic Metastasis 030220 oncology & carcinogenesis Cohort Female Radiology Sentinel Lymph Node business Follow-Up Studies |
Zdroj: | Journal of the American Academy of Dermatology. 80:722-726 |
ISSN: | 0190-9622 |
Popis: | Background Melanoma patients with negative nodes after sentinel lymph node biopsy are a heterogeneous group. Current guidelines fail to adequately stratify surveillance and treatment for this group. Also, there is scarce data on adjuvant treatments for these patients. Objective To create a nomogram including clinical and pathologic characteristics capable of evaluating the risk for recurrence of primary melanoma patients with negative sentinel lymph node biopsies (SLNBs). Methods We used a retrospective cohort of patients who underwent SLNB during 2000-2015 at a single institution. Results Our cohort comprised 1213 patients. Among these patients, 967 (79.7%) had a negative SLNB, and mean follow-up was 59.67 months. There were 133 recurrences (13.8%); 45 (33.8%) presented with nodal recurrence, and 35 (26.3%) recurred where a SLNB was performed. Breslow thickness, ulceration, and microsatellitosis were found to be predictive of risk for recurrence at 1, 2, 5, and 10 years. Limitation Single center analysis. Conclusion We created a predictive nomogram for melanoma patients with negative SLNBs. This nomogram is easy to use and identifies high-risk patients who should have more strict surveillance and be considered for adjuvant treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |